关于不同治疗模式的类风湿性关节炎进展性多焦点白细胞脑病变报告 - 使用食品和药物管理不良事件报告系统进行探索性评估
Takeshi Honma1, Kenji Onda2, Koichi Masuyama3
1Bohsei Pharmacy, Kanagawa, Japan.
Frontiers in drug safety and regulation
|September 22, 2025
概括
在类风湿性关节炎 (RA) 患者中,随着甲状腺素 (MTX) 和修仙药 (RIT) 联合治疗,渐进性多焦点白内障 (PML) 的风险增加. 年龄较大的男性也表现出PML风险增加.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药物监督 药物监督 药物监督
背景情况:
- 渐进性多焦点白内障 (PML) 是一种严重的脑部感染,与免疫抑制疗法有关.
- 甲基 (MTX) 是一种常见的类风湿性关节炎 (RA) 药物,人们对其与PML的关联存在担忧.
- 关于 RA 患者的药物联合作用和 PML 风险的数据有限.
研究的目的:
- 调查治疗模式和患者因子与RA中PML报告相关的患者因素.
- 评估同时服用药物对RA中PML风险的影响.
主要方法:
- 从FDA不良事件报告系统 (FAERS) 数据库 (1997-2019) 中分析RA病例.
- 计算各种药物和患者人口统计数据的原始和调整报告几率比率 (aROR).
主要成果:
- 对于MTX,利图西马布 (RIT),阿扎西奥普林和环胺的aROR升高.
- 同时使用MTX和RIT显示aROR高于单一治疗.
- 增加的PML报告与男性性别和年龄较大有关.
- TNF-α抑制剂或葡萄糖皮质类药物没有增加PML报告.
结论:
- 在RA患者中,MTX和RIT的组合可能与PML的风险增加有关.
- 老年男性在RA治疗的背景下似乎有更高的PML风险.
- 这些发现强调了在PML风险评估中考虑药物组合和患者因素的重要性.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Therapeutic Drug Monitoring: Affecting Factors
202
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
202
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Therapeutic Drug Monitoring: Overview and Classification
312
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
312


